The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer

BACKGROUND: To explore whether metastatic castration‐resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC‐P) subtypes respond differently to abiraterone and docetaxel treatment. METHODS: We retrospectively analyzed data of 170 mCRPC patients receiving a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhipeng, Zhu, Sha, Zhao, Jinge, Nie, Ling, Chen, Xueqin, Zhang, Mengni, Chen, Ni, Sun, Guangxi, Chen, Junru, Ni, Yuchao, Dai, Jindong, Liu, Zhenhua, Tao, Ronggui, Zhang, Xingming, Zhu, Xudong, Zhang, Haoran, Liang, Jiayu, Wang, Zilin, He, Ben, Shen, Pengfei, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290811/
https://www.ncbi.nlm.nih.gov/pubmed/34435696
http://dx.doi.org/10.1002/pros.24215
_version_ 1784748996905926656
author Wang, Zhipeng
Zhu, Sha
Zhao, Jinge
Nie, Ling
Chen, Xueqin
Zhang, Mengni
Chen, Ni
Sun, Guangxi
Chen, Junru
Ni, Yuchao
Dai, Jindong
Liu, Zhenhua
Tao, Ronggui
Zhang, Xingming
Zhu, Xudong
Zhang, Haoran
Liang, Jiayu
Wang, Zilin
He, Ben
Shen, Pengfei
Zeng, Hao
author_facet Wang, Zhipeng
Zhu, Sha
Zhao, Jinge
Nie, Ling
Chen, Xueqin
Zhang, Mengni
Chen, Ni
Sun, Guangxi
Chen, Junru
Ni, Yuchao
Dai, Jindong
Liu, Zhenhua
Tao, Ronggui
Zhang, Xingming
Zhu, Xudong
Zhang, Haoran
Liang, Jiayu
Wang, Zilin
He, Ben
Shen, Pengfei
Zeng, Hao
author_sort Wang, Zhipeng
collection PubMed
description BACKGROUND: To explore whether metastatic castration‐resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC‐P) subtypes respond differently to abiraterone and docetaxel treatment. METHODS: We retrospectively analyzed data of 170 mCRPC patients receiving abiraterone or docetaxel as first‐line therapy. PSA response, PSA progression‐free survival (PSA‐PFS), radiographic progression‐free survival (rPFS), and overall survival (OS) were analyzed based on the presence of IDC‐P and its subpatterns. RESULTS: IDC‐P was confirmed in 91/170 (53.5%) patients. Among them 36/91 (39.6%) and 55/91 (60.4%) harbored IDC‐P patterns 1 and 2, respectively. Patients with IDC‐P pattern 1 shared similar clinical outcomes to those without IDC‐P in both abiraterone and docetaxel treatment. However, against cases without IDC‐P or with IDC‐P pattern 1, patients with IDC‐P pattern 2 had markedly poorer prognosis in either abiraterone (mPSA‐PFS: 11.9 vs. 11.1 vs. 6.1 months, p < 0.001; mrPFS: 18.9 vs. 19.4 vs. 9.6 months, p < 0.001) or docetaxel (mPSA‐PFS: 6.2 vs. 6.6 vs. 3.0 months, p < 0.001; mrPFS: 15.1 vs. 12.6 vs. 5.5 months, p < 0.001) treatment. For patients without IDC‐P, docetaxel had comparable therapeutic efficacy with abiraterone. However, the efficacy of docetaxel was significantly inferior to abiraterone in patients with either IDC‐P pattern 1 (mPSA‐PFS: 6.6 vs. 11.1 months, p = 0.021; mrPFS: 12.6 vs. 19.4 months, p = 0.027) or pattern 2 (mPSA‐PFS: 3.0 vs. 6.1 months, p = 0.003; mrPFS: 5.5 vs. 9.6 months, p = 0.007). CONCLUSION: Compared to docetaxel, abiraterone exhibited better efficacy in patients with IDC‐P of either pattern. However, IDC‐P pattern 2 responded unsatisfactorily to either abiraterone or docetaxel therapy. Novel therapeutic strategies for IDC‐P pattern 2 need further investigations.
format Online
Article
Text
id pubmed-9290811
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92908112022-07-20 The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer Wang, Zhipeng Zhu, Sha Zhao, Jinge Nie, Ling Chen, Xueqin Zhang, Mengni Chen, Ni Sun, Guangxi Chen, Junru Ni, Yuchao Dai, Jindong Liu, Zhenhua Tao, Ronggui Zhang, Xingming Zhu, Xudong Zhang, Haoran Liang, Jiayu Wang, Zilin He, Ben Shen, Pengfei Zeng, Hao Prostate Original Articles BACKGROUND: To explore whether metastatic castration‐resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC‐P) subtypes respond differently to abiraterone and docetaxel treatment. METHODS: We retrospectively analyzed data of 170 mCRPC patients receiving abiraterone or docetaxel as first‐line therapy. PSA response, PSA progression‐free survival (PSA‐PFS), radiographic progression‐free survival (rPFS), and overall survival (OS) were analyzed based on the presence of IDC‐P and its subpatterns. RESULTS: IDC‐P was confirmed in 91/170 (53.5%) patients. Among them 36/91 (39.6%) and 55/91 (60.4%) harbored IDC‐P patterns 1 and 2, respectively. Patients with IDC‐P pattern 1 shared similar clinical outcomes to those without IDC‐P in both abiraterone and docetaxel treatment. However, against cases without IDC‐P or with IDC‐P pattern 1, patients with IDC‐P pattern 2 had markedly poorer prognosis in either abiraterone (mPSA‐PFS: 11.9 vs. 11.1 vs. 6.1 months, p < 0.001; mrPFS: 18.9 vs. 19.4 vs. 9.6 months, p < 0.001) or docetaxel (mPSA‐PFS: 6.2 vs. 6.6 vs. 3.0 months, p < 0.001; mrPFS: 15.1 vs. 12.6 vs. 5.5 months, p < 0.001) treatment. For patients without IDC‐P, docetaxel had comparable therapeutic efficacy with abiraterone. However, the efficacy of docetaxel was significantly inferior to abiraterone in patients with either IDC‐P pattern 1 (mPSA‐PFS: 6.6 vs. 11.1 months, p = 0.021; mrPFS: 12.6 vs. 19.4 months, p = 0.027) or pattern 2 (mPSA‐PFS: 3.0 vs. 6.1 months, p = 0.003; mrPFS: 5.5 vs. 9.6 months, p = 0.007). CONCLUSION: Compared to docetaxel, abiraterone exhibited better efficacy in patients with IDC‐P of either pattern. However, IDC‐P pattern 2 responded unsatisfactorily to either abiraterone or docetaxel therapy. Novel therapeutic strategies for IDC‐P pattern 2 need further investigations. John Wiley and Sons Inc. 2021-08-26 2021-11-01 /pmc/articles/PMC9290811/ /pubmed/34435696 http://dx.doi.org/10.1002/pros.24215 Text en © 2021 The Authors. The Prostate published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Wang, Zhipeng
Zhu, Sha
Zhao, Jinge
Nie, Ling
Chen, Xueqin
Zhang, Mengni
Chen, Ni
Sun, Guangxi
Chen, Junru
Ni, Yuchao
Dai, Jindong
Liu, Zhenhua
Tao, Ronggui
Zhang, Xingming
Zhu, Xudong
Zhang, Haoran
Liang, Jiayu
Wang, Zilin
He, Ben
Shen, Pengfei
Zeng, Hao
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
title The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
title_full The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
title_fullStr The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
title_full_unstemmed The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
title_short The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
title_sort heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290811/
https://www.ncbi.nlm.nih.gov/pubmed/34435696
http://dx.doi.org/10.1002/pros.24215
work_keys_str_mv AT wangzhipeng theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhusha theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhaojinge theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT nieling theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT chenxueqin theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhangmengni theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT chenni theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT sunguangxi theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT chenjunru theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT niyuchao theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT daijindong theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT liuzhenhua theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT taoronggui theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhangxingming theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhuxudong theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhanghaoran theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT liangjiayu theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT wangzilin theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT heben theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT shenpengfei theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zenghao theheterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT wangzhipeng heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhusha heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhaojinge heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT nieling heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT chenxueqin heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhangmengni heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT chenni heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT sunguangxi heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT chenjunru heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT niyuchao heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT daijindong heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT liuzhenhua heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT taoronggui heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhangxingming heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhuxudong heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zhanghaoran heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT liangjiayu heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT wangzilin heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT heben heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT shenpengfei heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer
AT zenghao heterogeneityofintraductalcarcinomaoftheprostateisassociatedwithdifferentefficacyofstandardfirstlinetherapyforpatientswithmetastaticcastrationresistantprostatecancer

Ejemplares similares